FABP4 Antibody - #DF6035

Fig. 1 rhIL-17A increased FABP4 expression in OvCa cells via STAT3 signaling. Dose–efect (a, b) and time–efect (c) experiments were performed in A2780 and OVCAR3 cells. a mRNA level of FABP4 after rhIL-17A treatment. b, c Protein expression of FABP4 after rhIL-17A treatment. d-(a) Protein expression of FABP4, p-STAT3 and STAT3 after rhIL-17A and/or STATTIC treatment (A2780: 0.3125  μM; OVCAR3: 1.25  μM). d-(b) The relative expression of proteins in d-(a). Three independent experiments were performed and a representative image is shown. Data represent the mean±SD from three independent experiments. *p<0.05, **p<0.01

Fig. 5. Identification of Exo in co-culture system supernatant, establishment of IR model and influence of GSY on it. A. TEM identification of Exo morphology and size-concentration distribution of Exo in the supernatant. B. Expression levels of Exo marker proteins CD9, CD63 and TSG101 in the supernatant of the co-culture system. C. Expression levels of PPARγ, GLUT4 and FABP4 genes in Exo supernatant of co-culture system. D. Glucose consumption in supernatant during the establishment of IR model in co-culture system. E. Glucose consumption rate in supernatant during the establishment of IR model in co-culture system. F. Glucose consumption rate after the establishment of IR model of co-culture system. J. Glucose consumption in the supernatant of each experimental group in the co-culture system. H. TG content in supernatant of each experimental group of co-culture system. I. Expression levels of PPARγ, GLUT4 and FABP4 proteins in the supernatant Exo of co-culture system after GSY intervention. J. Expression levels of PPARγ, GLUT4 and FABP4 genes in Exo after GSY intervention. *p < 0.05; **p < 0.01; ***p < 0.001. NC: Negative control; MOD: Model (60 mmol/L glucose). All experiments were repeated three times.